-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AHWqNVBawDEm4KQyq4CP5PRgdyh6/7ZQ/RxYNGbXtTYPyNzYPppLdttxj9uAKV5P RG5WATVcULiN7Mo5++vw5Q== 0001036050-00-000016.txt : 20000202 0001036050-00-000016.hdr.sgml : 20000202 ACCESSION NUMBER: 0001036050-00-000016 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20000107 FILED AS OF DATE: 20000111 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHOENIX INTERNATIONAL LIFE SCIENCES INC CENTRAL INDEX KEY: 0000935016 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 223209631 FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 6-K SEC ACT: SEC FILE NUMBER: 000-29942 FILM NUMBER: 505079 BUSINESS ADDRESS: STREET 1: 2350 COHEN STREET STREET 2: ST LAURENT QUEBEC CITY: H4R 2P7 CANADA STATE: A8 ZIP: 00000 6-K 1 FORM 6K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Dated January 11, 2000 PHOENIX INTERNATIONAL LIFE SCIENCES INC. ---------------------------------------- (Translation of registrant's name into English) 2350 Cohen Street ----------------- Saint Laurent, Quebec Canada H4R 2N6 ------------------------------------ (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ______ Form 40-F X (commenced in calendar ----- year 1998) Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ____ No X --- If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): ______________ SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PHOENIX INTERNATIONAL LIFE SCIENCES INC. ---------------------------------------- (Registrant) Date: January 11, 2000 By: /s/ David Moszkowski --------------- --------------------- David Moszkowski Senior Vice President and Chief Financial Officer EX-99.1 2 PRESS RELEASE DATED JANUARY 4, 2000 Exhibit 99.1 ------------ NEWS RELEASE PRESS RELEASE For immediate release PHOENIX INTERNATIONAL EXITS APPLICATIONS SOFTWARE BUSINESS Montreal, Quebec - January 4th, 2000- Phoenix International Life Sciences Inc. (NASDAQ: PHXI; TSE: PHX) today announced that it is exiting the commercial applications software business. This action results in a reduction of about 25 people in the company's Information Technology workforce. A project team of software specialists will be retained by Phoenix to service commercial clients and internal systems. "We are focusing our resources on what we do best. Applications software is not our expertise. We remain committed to supporting our existing clients, but Phoenix will no longer be involved in the future development and sale of scientific software for the pharmaceutical industry," said Ian Lennox, CEO of Phoenix International. Phoenix International earlier announced the spin-off of its scientific software division, Integraware. The intent of the new division was to independently develop and market new software for the pharmaceutical industry. Market conditions, Phoenix's need to gain access to the best applications software in development and a new focus on shareholder value prompted the change in strategic direction. About Phoenix International Phoenix International is one of the world's leading contract research organizations. The company is a global leader in early stage pharmaceutical development and has a growing presence in late stage pharmaceutical development. Headquartered in Montreal, Quebec, Phoenix International employs over 2,000 people in 19 countries around the world. Phoenix International is on the world- wide web at www.pils.com. This release contains "forward-looking" statements regarding future results and events, including statements regarding expected future revenues, earnings and growth rates and goals and operating plans of management. Phoenix's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Factors that may cause such a difference include, but are not limited to: the inability of Phoenix to win new business at the levels required; the cancellation or delay of contracts; risks associated with the management of growth and the ability to attract and retain employees; risks of integrating newly acquired businesses; competition; any claims for patent infringement; unanticipated costs in connection with Year 2000conversion; the ability to obtain future financing; adverse regulatory developments; foreign exchange rate fluctuations; and uncertainty surrounding the Euro. FOR MORE INFORMATION, PLEASE CONTACT: MEDIA: Richard Gareau Director of Communications Phoenix International Life Sciences Inc. Tel: (514) 333-0033, extension 4638 E-mail: richard.gareau@pils.com ANALYST CONTACT: DAVID MOSZKOWSKI, C.A. Senior Vice President and Chief Financial Officer Phoenix International Life Sciences Inc. Tel: (514) 333-0033 Fax: (514) 335-8351 E-mail: david.moszkowski@pils.com EX-99.2 3 PRESS RELEASE DATED JANUARY 10, 2000 Exhibit 99.2 ------------ NEWS RELEASE PRESS RELEASE For immediate release PHOENIX INTERNATIONAL AND CURAGEN LAUNCH ---------------------------------------- TRANSGENIC RESEARCH PROGRAM --------------------------- Montreal, Quebec -- January 10, 2000 - Phoenix International Life Sciences (NASDAQ:PHXI; TSE:PHX), one of the world's leading contract research organizations, today announced a transgenics science-based genomics research program between its subsidiary DNX Transgenic Sciences of Cranbury, NJ and CuraGen Corporation of New Haven, CT (NASDAQ: CRGN), an integrated genomics- based drug discovery and development company. Under the terms of the agreement, Phoenix International's DNX Transgenic Sciences subsidiary will develop transgenic mice based upon a large number of novel gene constructs provided by CuraGen. CuraGen will utilize these mice to identify novel therapeutic protein drugs appropriate for further development. "We are eager to begin working with a genomics focused company like CuraGen in applying our high capacity transgenic capabilities to the drug development process. Our new facilities in Cranbury are well suited for such high throughput efforts," said Mark Swanson, Vice President-Transgenic Sciences. "With only about 5,000 human genes characterized to date and an estimated 140,000 total human genes soon to be identified, we are preparing for many more contracts of this type." "This agreement strengthens CuraGen's ability to deduce the therapeutic utility of proprietary genes identified through CuraGen's suite of genomics technologies and databases," stated Henri Lichenstein, Ph.D., Director of Drug Development for CuraGen. "We look forward to utilizing the proven technology of transgenic mice to accelerate CuraGen's internal protein therapeutic drug program." Throughout the duration of the 3-year research agreement, CuraGen will fund the development and characterization of transgenic mice from at least 45 unique gene constructs. DNX and CuraGen will jointly genotype, select and characterize over 135 transgenic mouse lines in a flexible collaborative research program. The transgenic research will take place in DNX's newly expanded research facilities in Cranbury, NJ. The use of transgenic animal science has become an important genomics tool to assist in the identification of novel protein therapeutics and targets for pharmaceutical intervention. CuraGen Corporation is advancing the discovery and development of pharmaceutical and life science products through the systematic application of genomics. CuraGen's fully integrated, Internet-based genomics technologies, services, and information systems are designed to rapidly generate comprehensive information about genes, human genetic variations, gene expression, biological pathways, and potential products that affect these pathways. CuraGen's strategic collaborators include Abgenix, Biogen, COR Therapeutics, Genentech, Glaxo Wellcome, Hoffmann- La Roche, Pioneer Hi-Bred International, and Roche Vitamins. The Company employs approximately 300 people and is headquartered in New Haven, CT, with additional facilities in Branford, CT and Alachua, FL. Additional Company information is available at www.curagen.com. - --------------- DNX Transgenic Sciences, a wholly owned subsidiary of Phoenix International Life Sciences, is a contract research organization providing transgenic animal technologies to the worldwide biomedical research community. DNX integrates its proprietary transgenic and gene targeting technologies, molecular biology, animal science, and phenotypic analysis capabilities into customized research programs for its clients to assist in the identification of new drug targets and novel protein therapeutics and to provide specifically engineered animal models for evaluation of therapeutic strategies. Phoenix International is one of the world's leading contract research organizations. The Company is a global leader in early stage pharmaceutical development and has a growing presence in late stage pharmacetical development. Headquarted in Montreal, Quebec, the Company employs over 2,000 people in 19 countries around the world. Phoenix International is on the worldwide web at www.pils.com. - ------------ This release contains "forward-looking" statements regarding future results and events, including statements regarding expected future revenues, earnings and growth rates and goals and operating plans of management. Phoenix's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Factors that may cause such a difference include, but are not limited to: the inability of Phoenix to win new business at the levels required; the cancellation or delay of contracts; risks associated with the management of growth and the ability to attract and retain employees; risks of integrating newly acquired businesses; competition; any claims for patent infringement; unanticipated costs in connection with Year 2000 conversion; the ability to obtain future financing; adverse regulatory developments; foreign exchange rate fluctuations; and uncertainty surrounding the Euro. For more information, please contact: Analysts: David Moszkowski, C.A. Senior Vice President and Chief Financial Officer Phoenix International Life Sciences, Inc. Tel: (514) 333-0033, Fax: (514) 335-8351 E-mail: david.moszkowski@pils.com ------------------------- Media: Richard Gareau Director of Communications Phoenix International Life Sciences, Inc. Tel: (514) 333-0033, Fax: (514) 335-8351 E-mail: richard.gareau@pils.com --------------- Mark R. Vincent Director, Corporate Communications mvincent@curagen.com CuraGen Corporation 1-888-GENOMICS www.curagen.com - --------------- -----END PRIVACY-ENHANCED MESSAGE-----